Cardiovascular and renal outcomes with varying degrees of kidney disease in high-risk people with type 2 diabetes: An epidemiological analysis of data from the AMPLITUDE-O trial.

Gerstein HC, Mian R, Ramasundarahettige C, Branch KRH, Del Prato S, Lam CSP, Lopes RD, Pratley R, Rosenstock J, Sattar N

Diabetes, obesity & metabolism20 Dec 2023Cited by 2 (Europe PMC)

PMID38116691DOI10.1111/dom.15417PepBankPUB-38116691

Publisher page PubMedAsk about this study

Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

01HumanObservational studyEfficacy outcome
In high-risk people with diabetes, efpeglenatide's MACE effect did not vary with kidney disease measures; all interaction p values were ≥0.26.
In plain wordsIn high-risk people with diabetes, efpeglenatide's MACE effect did not vary with kidney disease measures.
Peptide
Efpeglenatide
Outcome
No significant changeMACE effect modification by kidney disease
Study
n = 3,983
Comparator
Kidney disease measures: eGFR, UACR and KDIGO category
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
Dose not stated
Measurements
Interaction p value
≥ 0.26
efpeglenatide by eGFR, UACR and KDIGO category, MACE
Source sentences
Summary
Efpeglenatide's effect on both outcomes did not vary with any kidney disease measure (all interaction p values ≥0.26).
2 context sentences(design, population, supporting numbers)
Summary · context
AMPLITUDE-O trial data were used to estimate the relationship of eGFR, UACR, and Kidney Disease Improving Global Outcomes (KDIGO) category to the hazard of MACE and the kidney composite.
Summary · context
Interactions on these outcomes between eGFR and the UACR, and between each of these variables and efpeglenatide were also assessed.
Report a problemFND-3811669101
02HumanObservational studyEfficacy outcome
In high-risk people with diabetes, efpeglenatide's kidney composite effect did not vary with kidney disease measures; all interaction p values were ≥0.26.
In plain wordsIn high-risk people with diabetes, efpeglenatide's kidney composite effect did not vary with kidney disease measures.
Peptide
Efpeglenatide
Outcome
No significant changeKidney composite effect modification
Study
n = 3,983
Comparator
Kidney disease measures: eGFR, UACR and KDIGO category
Outcome group
Kidney function · Kidney and urinary
Studied dose
Dose not stated
Measurements
Interaction p value
≥ 0.26
efpeglenatide by eGFR, UACR and KDIGO category, kidney composite
Source sentences
Summary
Efpeglenatide's effect on both outcomes did not vary with any kidney disease measure (all interaction p values ≥0.26).
2 context sentences(design, population, supporting numbers)
Summary · context
AMPLITUDE-O trial data were used to estimate the relationship of eGFR, UACR, and Kidney Disease Improving Global Outcomes (KDIGO) category to the hazard of MACE and the kidney composite.
Summary · context
Interactions on these outcomes between eGFR and the UACR, and between each of these variables and efpeglenatide were also assessed.
Report a problemFND-3811669102

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
27 Oct 2026, 18:20 UTC
Study results updated
Version 1
27 Oct 2026, 16:32 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.